TBPH Theravance Biopharma, Inc.
8-K Current Report
Filed: March 3, 2026
Health Care
Pharmaceutical PreparationsTheravance Biopharma, Inc. (TBPH) 8-K current report filed with SEC EDGAR on March 3, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items2 items
- Item 2.02: Results of Operations and Financial Condition
- Item 2.05: Costs Associated with Exit or Disposal Activities
AI Filing Analysis8-K
Item 2.02 · Results of Operations and Financial Condition
- • YUPELRI sales growth and royalty payments cited as key forward-looking focus areas for the company
- • Ampreloxetine program and R&D function being wound down; G&A also significantly reduced — signals major cost restructuring underway
Item 2.05 · Costs Associated with Exit or Disposal Activities
- • Workforce cut ~50%, cost base reduced ~60% (~$70M in annual savings)
- • One-time cash severance costs estimated $5M–$7M over next two quarters
Other Theravance Biopharma, Inc. 8-K Filings
Get deeper insights on Theravance Biopharma, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.